Biomed reports positive Phase 2/3 Rett syndrome data for NA-921
Biomed Industries said its investigational oral therapy NA-921 met both coprimary endpoints in a Phase 2/3 study of girls and women with Rett syndrome, with favorable tolerability. The company presented the results at the World Pediatrics Conference in Osaka and outlined a planned Phase 3 trial of 210 participants.
Why it matters: - Rett syndrome has no widely effective treatment that addresses both symptoms and tolerability across a broad patient population. - Positive midstage data for NA-921 could help Biomed Industries advance a new oral option for girls and women living with the rare neurodevelopmental disorder. - The results may support a larger Phase 3 program if the findings hold up in a broader study.
What happened: - Biomed Industries presented positive Phase 2/3 clinical results for NA-921, also called Bionetide™, at the World Pediatrics Conference on Oct. 5-6 in Osaka, Japan. - Dr. Lloyd L. Tran, Biomed Industries CEO, delivered the presentation titled “Reimagining Rett Syndrome Treatment: Phase 2/3 Clinical Results of NA-921 Demonstrating Efficacy and Favorable Tolerability.” - The randomized, double-blind, placebo-controlled study was registered on ClinicalTrials.gov as NCT06849973. - The trial evaluated oral NA-921 in females ages 5 to 20 with Rett syndrome. - The study included 173 participants, with 86 receiving NA-921 and 87 receiving placebo.
The details: - NA-921 produced statistically significant improvement on both coprimary endpoints over 12 weeks. - On the Rett Syndrome Behavior Questionnaire, the least-squares mean change from baseline was -5.5 points with NA-921 versus -1.6 points with placebo, a 3.9-point difference favoring NA-921 (p=0.001). - Lower Rett Syndrome Behavior Questionnaire scores indicate reduced symptom severity. - On the Clinical Global Impression-Improvement scale, scores were 3.60 with NA-921 and 3.83 with placebo (p=0.002). - Lower Clinical Global Impression-Improvement scores indicate greater clinician-rated improvement. - The study also tracked a key secondary objective focused on communication ability. - The conference abstract said NA-921 was generally well tolerated. - Gastrointestinal adverse events were mild and occurred at rates comparable with placebo. - No serious adverse events were reported. - No participants discontinued treatment, needed dose reductions, or withdrew because of adverse events. - Biomed also outlined a Phase 3 randomized, double-blind, placebo-controlled study registered as NCT06840496. - The planned Phase 3 trial targets 210 participants. - The Phase 3 program is designed to further evaluate Rett syndrome symptoms, overall clinical improvement, and communication ability as a key secondary assessment.
Between the lines: - The main commercial and clinical question is whether the treatment effect and tolerability can scale from a 173-patient study into a larger confirmatory trial. - The lack of serious adverse events and treatment discontinuations is important because Rett syndrome therapies often need to balance efficacy against long-term tolerability. - Biomed’s emphasis on communication ability suggests the company is positioning NA-921 around functional outcomes, not only symptom scores. - The presentation and follow-on Phase 3 plan signal that Biomed is using these data as a bridge to later-stage development, but the results still need confirmation.
What's next: - Biomed will move ahead with Phase 3 development of NA-921 if the program proceeds as outlined. - Larger studies and longer follow-up are needed to better define efficacy, safety, and durability of benefit. - The company disclosed that NA-921 remains investigational and has not been approved for marketing. - Forward-looking statements in the release note that clinical outcomes, regulatory requirements, financing, and timelines could affect development.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The MarCom Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.